drugset

Drugs / Alalevonadifloxacin

Follow last change Jan 2020 re-read 3 minutes ago

Alalevonadifloxacin

also known as WCK 2349

Investigated by: Clinartis · Wockhardt

Trials 1

today NCT02253342 · Ph 1

2015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT02253342	Sep → Dec 2014	—	Wockhardt	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2020-01-16	Wockhardt	Regulatory INDIA’S FIRST NEW DISCOVERY ANTIBIOTICS FROM WOCKHARDT GRANTED INDIAN REGULATORY APPROVAL wockhardt.com ↗ India’s First New Discovery Antibiotics from Wockhardt Granted Indian Regulatory Approval

All press releases naming this drug 1 release

Date	Issuer	Release
2020-01-16	Wockhardt	INDIA’S FIRST NEW DISCOVERY ANTIBIOTICS FROM WOCKHARDT GRANTED INDIAN REGULATORY APPROVAL wockhardt.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Alalevonadifloxacin	“Alalevonadifloxacin (WCK 2349) is a novel l-alanine ester prodrug of levonadifloxacin that is being developed as an oral fluoroquinolone antibiotic.” PMID 29263070 ↗ Feb 2018
Known as	WCK 2349	“Alalevonadifloxacin (WCK 2349) is a novel l-alanine ester prodrug of levonadifloxacin that is being developed as an oral fluoroquinolone antibiotic.” PMID 29263070 ↗ Feb 2018
Modality	Small molecule	“being developed as an oral fluoroquinolone antibiotic” PMID 29263070 ↗ Feb 2018
Route	Oral	“following oral dosing of alalevonadifloxacin” PMID 29263070 ↗ Feb 2018